GlassScriptPhysician profile
Hanna Thomas
NPI 1194035667
$66,585.78
in general payments reported to CMS, 2019-2025
22 companies · $20K in 2025
The $20K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $2,866 · 2021: $6,361 · 2022: $6,627 · 2023: $3,171 · 2024: $18K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Food and Beverage: $3,489 · Travel and Lodging: $166 · Education: $77.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,655.00 |
| Food and Beverage | $3,489.49 |
| Travel and Lodging | $165.67 |
| Education | $77.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $38,521.77 | 2021-2025 | |
| Vifor Pharma, INC. | $24,428.01 | 2019-2023 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $886.48 | 2019-2025 | Farxiga, Lokelma |
| Daiichi Sankyo INC. | $732.17 | 2019-2023 | Injectafer |
| Calliditas Therapeutics US INC. | $327.11 | 2023-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $282.20 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $272.35 | 2020-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $187.19 | 2019-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $164.02 | 2023-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $163.54 | 2021-2023 | Jesduvroq, Benlysta |
| Horizon Therapeutics Plc | $152.14 | 2022-2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $125.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $83.03 | 2024-2025 | |
| Amgen INC. | $56.36 | 2024-2025 | Tavneos |
| Fresenius USA Marketing, INC. | $53.63 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.07 | 2024-2025 | Jardiance |
| Renalytix Ai, INC. | $33.68 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Advanced Oxygen Therapy INC. | $29.38 | 2025 | Topical Oxygen Chamber For Extremities |
| Novo Nordisk INC | $18.29 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.88 | 2025 | |
| Outset Medical INC | $10.48 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hanna Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.